Abstract 1485P
Background
Patients (pts) diagnosed with metastatic cancer often experience a high symptom burden and diminished health-related quality of life (HRQOL), which can significantly impact their overall well-being. Physical activity (PA) has emerged as a promising intervention to alleviate symptoms and improve HRQOL in this population. This study examines the effects of a 12-week supervised remote PA program on symptom burden and health-related quality of life (HRQOL) in pts diagnosed with metastatic cancer.
Methods
This prospective study included eligible pts undergoing treatment for metastatic cancer. Initial assessments and weekly exercise guidance were provided to pts via WhatsApp. Proper home exercise techniques were demonstrated using the Vedius platform. The prescribed exercise regimen entailed 3 to 5 hours per week (4 to 6 days a week) of combined resistance and aerobic exercises. Outcome measures, including symptom burden (Edmonton Symptom Assessment System, ESAS, scale 0-90) and overall quality of life (Functional Assessment of Cancer Therapy-General, FACT-G, scale 0-108) were evaluated at baseline and after 12 weeks. Data analysis involved descriptive statistics and the linear mixed models.
Results
A total of 62 pts, with a median age of 68 years (range: 32-88), were enrolled in the study. Among the participants, 54.8% were female, 66.1% were white, and 61.3% were married, with 57.7% holding a college degree. The most prevalent cancer types included breast (24.2%), genitourinary (19.4%), lung (14.5%), and gynecological (14.5%). Over the study period, a significant improvement was observed in symptom burden (baseline mean=21.7, follow-up mean=7.8, P=0.001) and HRQOL (baseline mean=83.4, follow-up mean=95.4, P=0.001).
Conclusions
Our findings demonstrates that a 12-week supervised remote PA program has a significant positive impact on symptom burden and HRQOL in pts with metastatic cancer undergoing treatment. These findings underscore the potential benefits of incorporating PA interventions into the management of metastatic cancer, offering a promising avenue for improving patient outcomes and well-being.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10